Amy C. Moore, PhD
banner
acmoorephd.bsky.social
Amy C. Moore, PhD
@acmoorephd.bsky.social
Internationally-recognized KOL and patient advocate. Director, Patient Engagement & Advocacy at Summit Therapeutics.
Views = my own
Pinned
Humbled to be included on @oncodaily.bsky.social's list of 100 Influential Women in Oncology for 2024. Check out the full list of the trailblazers who are changing the face of cancer research, patient care and advocacy around the globe oncodaily.com/positive/100...
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024 - OncoDaily
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024 / 100 Influential Women in Oncology, 100 Questions and Answers about
oncodaily.com
Kiss them. They’re Irish. ☘️ 🌈
March 16, 2025 at 11:52 PM
Digging around in the basement and found this old award from AACR broken. But I glued it back together. Because science may be down right now, but it’s not out. We will put the pieces back together.
February 23, 2025 at 1:16 AM
Reposted by Amy C. Moore, PhD
Here is the pre-RFK vaccination schedule for your kids. Please download it before he is confirmed and changes/deletes it.

Give it to your pediatrician and say this is the schedule you want your kids on.

Making this my pinned post.
February 4, 2025 at 9:01 PM
I am proud to have worked with LUNGevity’s partners to develop these #lungcancer resources for members of the AANHPI community lungevity.org/health-equity #LCSM
February 2, 2025 at 5:12 PM
Reposted by Amy C. Moore, PhD
As February begins, we embrace a month dedicated to recognizing the extraordinary achievements of Black individuals who have shaped our world. Their stories inspire us to rise, challenge the status quo, and create a future filled with hope and progress.
February 1, 2025 at 6:56 PM
Reposted by Amy C. Moore, PhD
I’m an NSF panel reviewer that was scheduled to meet today. Just got notice that all NSF panels were canceled today. I reviewed some innovative proposals in support of students. Devastating if these scholars don’t get to do this work. For the love of science & students I hope this is just a delay.💔
January 27, 2025 at 2:45 PM
Having landed my first job outside my postdoc through a cold email, I know the power of that communication and how it can open doors www.nature.com/articles/d41...
Four tips for writing the perfect ‘cold e-mail’ in job applications
These strategies can transform your unsolicited applications from forgettable to fabulous.
www.nature.com
January 27, 2025 at 3:45 PM
As a scientist and an advocate, I am grateful for LUNGevity's commitment to continue to work on behalf of ALL people at risk for and impacted by #lungcancer as well as the researchers working to find new treatments. #LCSM
LUNGevity is unwavering in our commitment to funding high-quality lung cancer research, supporting patients and their families, and advocating for health equity, increased awareness, early detection, and improved treatments for lung cancer.
January 27, 2025 at 3:43 PM
The good news is my ping pong game has really improved this week. Burning off some steam!
a cat is sitting on a ping pong table looking at a blue balloon .
ALT: a cat is sitting on a ping pong table looking at a blue balloon .
media.tenor.com
January 25, 2025 at 8:08 PM
Reposted by Amy C. Moore, PhD
As a cancer patient community, we are lost for words. Science and research is what keeps us all going.

As Dr @choo.bsky.social said, “There are real people, real lives waiting on the science.”

nature.com/articles/d4158…#LCSMSM
January 25, 2025 at 9:58 AM
A good distraction from a cat-astrophic week for science
January 25, 2025 at 3:54 AM
One of my frustrations with our work to understand the causes of #cancer #cachexia as part of Cancer Grand Challenges Team #CANCAN is the limitation of animal models that don't reflect the realities of the patient population. This development helps. #LCSM #lungcancer

www.biorxiv.org/content/10.1...
Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancer
PIK3CA mutation is frequently concurrent with known oncogenic drivers such as EGFR mutation in lung cancer, raising an interesting question about its real function. Cachexia is a systemic disease invo...
www.biorxiv.org
January 23, 2025 at 7:52 PM
On this day 13 years ago, I was speaking at the Georgia Capitol about the importance of #cancer #research.

Despite what happened yesterday, we continue our work on behalf of those around the world at risk for, living with or impacted by #cancer.
January 23, 2025 at 12:30 PM
Reposted by Amy C. Moore, PhD
"Any prolonged pause of the #NIH’s study sections could result in funding delays for scientific labs awaiting approval of their work." #CanSky #MedSky #IDSky

www.statnews.com/2025/01/22/t...
Trump administration’s abrupt cancellation of scientific meetings prompts confusion, concern
A flurry of scientific gatherings and panels across federal science agencies were canceled on Wednesday, at a time of heightened sensitivity about how the
www.statnews.com
January 23, 2025 at 5:30 AM
Reposted by Amy C. Moore, PhD
First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC #lcsm #oncology www.onclive.com/view/first-l...
First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC
The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.
www.onclive.com
January 21, 2025 at 4:12 PM
My cat may be slightly spoiled
January 20, 2025 at 2:23 PM
Reposted by Amy C. Moore, PhD
9.5% MET and 7.9% EGFR detected in pts w lung SqCC with no smoking history.

Important to improve testing in this group. We are finding more of this with reflex testing in early stage disease.

#lcsm
January 19, 2025 at 4:48 PM
We still have a long way to go to ensure that ALL patients benefit from recent scientific advances in #lungcancer. This study found that overall survival increased by 71% in patients with private insurance compared to only 24% in the uninsured in the US. #LCSM

www.jtocrr.org/article/S266...
Recent Survival Gains in Stage IV Non-Small Cell Lung Cancer by Sociodemographic Strata
The management of stage IV non-small cell lung cancer (NSCLC) has been transformed by recent innovations. However, access to medical innovations can be variable across sociodemographic groups in the U...
www.jtocrr.org
January 19, 2025 at 3:59 PM
Biomarker testing can help identify actionable mutations in patients with SqNSCLC, especially in those without a history of smoking. Testing is not performed consistently in this setting. #LCSM #lungcancer

www.sciencedirect.com/science/arti...
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking
Next-generation sequencing (NGS) to detect actionable genomic driver alterations (AGAs) is critical to appropriate management of non-small cell lung c…
www.sciencedirect.com
January 19, 2025 at 3:58 PM
Reposted by Amy C. Moore, PhD
Excellent review of lung neuroendocrine neoplasms by Dr Sen,
@naglaakarimmd.bsky.social and team! Terrific discussion of molecular landscape, existing therapeutic challenges, and diagnosis & management strategies.
#LCSM #LungNETs #SCLC
@thelancet.bsky.social

www.thelancet.com/journals/lan...
January 7, 2025 at 2:58 AM